About Ajax Therapeutics
Ajax Therapeutics is a private company based in New York, New York, incorporated in 2019 in Delaware. It has reported $140,382,554 raised in three offerings on Form D since June 2019. Its chief executive is Martin Vogelbaum.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Apr 26, 2024 | May 13, 2024 | $95,000,000fully sold | 21 | $4.5M | EquityRule 506(b) | Form D ↗ |
| May 17, 2021 | Jun 1, 2021 | $37,382,554of $40.0M target | 14 | $2.6M | EquityRule 506(b) | Form D ↗ |
| Jun 12, 2019 | Jun 28, 2019 | $8,000,000fully sold | 6 | $1.3M | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $140,382,554 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Ajax Therapeutics's Form D filed May 13, 2024.
MV
Martin Vogelbaum
Chief Executive Officer and director
RL
Ross Levine
Director
SP
Scott Platshon
Director
RF
Ramy Farid
Director
Earlier filings also listed David Schnell (director, last listed Jun 2019).